Skip to content
Menu

COMPASS Pathways plc CMPS

Full chart Compare
Set alert

Price alert · CMPS

All alert types
8.11 USD -0.54 (-6.30%)

As ofNov 20, 2026, 11:49 AM EST

7.82 Day range 8.43
4.88 52-week range 15.87
YTD
+17.46%
1 year
+55.87%

5D -0.81 (-9.08%)

88.509MonTueWedThuFri8.11
Market cap
1.15B
EPS (ttm)
-2.34
Shares out
141.71M
Forward P/E
-5.47
YTD return
+17.46%
1-year return
+55.87%
50-day average
11.53
200-day average
10.51
Enterprise value
761.10M
Price / book
8.62
Volume
2.34M
Avg volume
3.03M
Open
8.32
Previous close
8.65
Day's range
7.82 – 8.43
52-week range
4.88 – 15.87
Beta
2.41
Analysts
Strong Buy
Price target
23.31 (+187.6%)
Earnings date
Mar 23, 2027

Key statistics

Free cash flow
36.26M
Total cash
443.98M
Total debt
54.39M
Return on equity
-296.45%
Short % of float
12.29%

Fundamental scorecard

3 of 25 checks passed on CMPS’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CMPS Revenue — quarterly 0
CMPS Net income — quarterly -9.83M
CMPS EPS — quarterly -0.07

Earnings

CMPS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 23, 2027Dec 30, 2026-0.40———
Nov 3, 2026Sep 30, 2026-0.39-0.31+0.08+20.51%
Aug 5, 2026Jun 30, 2026-0.46-0.36+0.10+21.74%
May 13, 2026Mar 31, 2026-0.45-0.30+0.15+33.33%
Mar 24, 2026Dec 31, 2025-0.41-1.00-0.59-143.90%
Nov 4, 2025Sep 30, 2025-0.40-1.44-1.04-260.00%

Upgrades / downgrades

CMPS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026HC Wainwright & Co.reitBuyBuy
Nov 4, 2026Wells FargomainEqual-WeightEqual-Weight
Nov 3, 2026BTIGreitBuyBuy
Aug 7, 2026HC Wainwright & Co.mainBuyBuy
Aug 6, 2026Morgan StanleymainOverweightOverweight
Aug 6, 2026RBC CapitalmainOutperformOutperform

About COMPASS Pathways plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Sector
Healthcare
Industry
Medical Care Facilities
Country
United Kingdom

News

Your note

Sign in to keep a note on CMPS — it syncs with the Stock Master app.

Insider holders

CMPS insider holders
InsiderRelationLatest transactionDateShares held
LOXAM TERIChief Financial OfficerStock Award(Grant)Mar 25, 2026152,002
NATH KABIRChief Executive OfficerStock Award(Grant)Mar 25, 2026366,990

Institution ownership

CMPS institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp8.58%12,161,496105.20MSep 29, 2026
RTW Investments LP7.73%10,948,59194.71MSep 29, 2026
BIT Capital GmbH6.33%8,968,09477.57MSep 29, 2026
Tang Capital Management, LLC3.67%5,200,00044.98MSep 29, 2026
ARK Investment Management, LLC3.46%4,905,61342.43MSep 29, 2026
Point72 Asset Management, L.P.3.34%4,737,70640.98MSep 29, 2026

Fund ownership

CMPS fund ownership
Holder% heldSharesValueReported
ARK ETF Trust-ARK Genomic Revolution ETF3.57%5,058,58343.76MOct 30, 2026
iShares Trust-iShares Biotechnology ETF0.63%886,6797.67MSep 29, 2026
AdvisorShares Trust-AdvisorShares Psychedelics ETF0.32%458,3953.97MOct 30, 2026
ROYCE FUND-Royce Smaller-Companies Growth Fund0.13%178,0001.54MJun 29, 2026
ALPS ETF TRUST-ALPS Medical Breakthroughs ETF0.12%166,5011.44MAug 30, 2026
Goldman Sachs Trust-Goldman Sachs Small Cap Growth Fund0.11%152,3011.32MAug 30, 2026